Anti-CD38 MAb, 1,2,3,>=4 prior line of therapy, Lenalidomide Exposed, Relapsed Refractory Multiple Myeloma (RRMM), Pomalidomide+Dexamethasone (Pd), Phase 3, Daratumumab+Pomalidomide+Dexamethasone (DPd)
### Instruction:
Identify the study with the following condition. 
### Input:
Anti-CD38 MAb, 1,2,3,>=4 prior line of therapy, Lenalidomide Exposed, Relapsed Refractory Multiple Myeloma (RRMM), Pomalidomide+Dexamethasone (Pd), Phase 3, Daratumumab+Pomalidomide+Dexamethasone (DPd) 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736